Paolo G Casali

Summary

Affiliation: Istituto Nazionale Tumori
Country: Italy

Publications

  1. ncbi request reprint Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas
    P G Casali
    Adult Mesenchymal Tumour Medical Oncology Unit, Istituto Nazionale Tumori, Milano, Italy
    Ann Oncol 23:x167-9. 2012
  2. doi request reprint Adjuvant therapy of gastrointestinal stromal tumors (GIST)
    Paolo G Casali
    Adult Mesenchymal Tumour Medical Oncology Unit, Istituto Nazionale Tumori, Via G Venezian 1, 20133, Milano, Italy
    Curr Treat Options Oncol 13:277-84. 2012
  3. doi request reprint Trabectedin therapy for sarcomas
    Paolo G Casali
    Adult Sarcoma Medical Unit, Istituto Nazionale Tumori, Milan, Italy
    Curr Opin Oncol 22:342-6. 2010
  4. ncbi request reprint Adjuvant chemotherapy for soft tissue sarcoma
    Paolo G Casali
    Adult Sarcoma Medical Oncology Unit, Istituto Nazionale Tumori, Milano, Italy
    Curr Opin Oncol 17:361-5. 2005
  5. ncbi request reprint Chordoma
    Paolo G Casali
    Adult Sarcoma Medical Oncology Unit, Istituto Nazionale dei Tumori, Milano, Italy
    Curr Opin Oncol 19:367-70. 2007
  6. ncbi request reprint Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors
    P G Casali
    Cancer Medicine Department, Istituto Nazionale Tumori, Milano, Italy
    J Chemother 16:55-8. 2004
  7. ncbi request reprint Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution
    Marco Fiore
    Department of Surgery, National Cancer Institute, Milan, Italy
    Cancer 109:2522-31. 2007
  8. ncbi request reprint Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution
    Andrea Ferrari
    Pediatric Oncology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer 101:627-34. 2004
  9. ncbi request reprint c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors
    Francesca C Miselli
    Experimental Molecular Pathology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy
    Clin Cancer Res 13:2369-77. 2007
  10. doi request reprint Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response
    Silvia Stacchiotti
    Adult Sarcoma Medical Oncology Unit, Department of Cancer Medicine, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milan, Italy
    Mol Cancer Ther 9:1286-97. 2010

Detail Information

Publications67

  1. ncbi request reprint Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas
    P G Casali
    Adult Mesenchymal Tumour Medical Oncology Unit, Istituto Nazionale Tumori, Milano, Italy
    Ann Oncol 23:x167-9. 2012
    ..all this highlights the current need for new methods to do clinical studies on rare cancers, amid highly specific though anecdotal proofs and less specific though statistically more powerful evidence...
  2. doi request reprint Adjuvant therapy of gastrointestinal stromal tumors (GIST)
    Paolo G Casali
    Adult Mesenchymal Tumour Medical Oncology Unit, Istituto Nazionale Tumori, Via G Venezian 1, 20133, Milano, Italy
    Curr Treat Options Oncol 13:277-84. 2012
    ..There are several instances in which part of the "adjuvant" treatment may be administered preoperatively, even on the face of a surgically resectable GIST, to make surgery more limited and/or safer...
  3. doi request reprint Trabectedin therapy for sarcomas
    Paolo G Casali
    Adult Sarcoma Medical Unit, Istituto Nazionale Tumori, Milan, Italy
    Curr Opin Oncol 22:342-6. 2010
    ..This was also due to increased consideration of their variegated histology. Trabectedin is a new chemotherapeutic agent, which significantly strengthens the armamentarium along this direction...
  4. ncbi request reprint Adjuvant chemotherapy for soft tissue sarcoma
    Paolo G Casali
    Adult Sarcoma Medical Oncology Unit, Istituto Nazionale Tumori, Milano, Italy
    Curr Opin Oncol 17:361-5. 2005
    ..To review current state-of-the-art knowledge about adjuvant medical therapy in adult soft tissue sarcomas...
  5. ncbi request reprint Chordoma
    Paolo G Casali
    Adult Sarcoma Medical Oncology Unit, Istituto Nazionale dei Tumori, Milano, Italy
    Curr Opin Oncol 19:367-70. 2007
    ..To review developments in chordoma treatment...
  6. ncbi request reprint Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors
    P G Casali
    Cancer Medicine Department, Istituto Nazionale Tumori, Milano, Italy
    J Chemother 16:55-8. 2004
    ..Its eradicating capabilities, as well as the implications of secondary resistance, are to be understood. 7) Integrated, multimodality approaches, including surgery, may still be of value in the molecular-targeted therapy era...
  7. ncbi request reprint Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution
    Marco Fiore
    Department of Surgery, National Cancer Institute, Milan, Italy
    Cancer 109:2522-31. 2007
    ..The objective of this study was to investigate prognostic factors and clinical outcome of myxoid/round cell and pleomorphic liposarcoma...
  8. ncbi request reprint Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution
    Andrea Ferrari
    Pediatric Oncology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer 101:627-34. 2004
    ..The current retrospective analysis examined a large group of patients of all ages who were treated at a single institution over a 30-year period...
  9. ncbi request reprint c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors
    Francesca C Miselli
    Experimental Molecular Pathology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy
    Clin Cancer Res 13:2369-77. 2007
    ..To correlate morphologic changes with molecular, biochemical, and cytogenetic profiles in gastrointestinal stromal tumor (GIST) patients before and after imatinib treatment...
  10. doi request reprint Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response
    Silvia Stacchiotti
    Adult Sarcoma Medical Oncology Unit, Department of Cancer Medicine, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milan, Italy
    Mol Cancer Ther 9:1286-97. 2010
    ..SM has antitumor activity in SFT, possibly through a PDGFRB-mediated mechanism, but treatments with IGFIR/insulin receptor and possibly epidermal growth factor receptor inhibitors are worth testing...
  11. ncbi request reprint Fluorescence in situ hybridization analysis and immunophenotyping of c-Kit/PDGFRA and Bcl-2 expression in gastrointestinal stromal tumors
    Marta Orsenigo
    Unit of Experimental Molecular Pathology, Department of Pathology, Fondazione Istituto di Ricerca e di Cura a Carattere Scientifico IRCCS, Istituto Nazionale dei Tumori, Milan, Italy
    Anal Quant Cytol Histol 32:225-33. 2010
    ..To investigate c-Kit/PDGFRA genomic alterations, KIT-PDGFRA coexpression in gastrointestinal stromal tumors (GISTs) and the role of Bcl-2...
  12. ncbi request reprint Prognostic effect of re-excision in adult soft tissue sarcoma of the extremity
    Marco Fiore
    Department of Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian, 1, Milan, 20133, Italy
    Ann Surg Oncol 13:110-7. 2006
    ..We explored the outcome of patients with primary adult soft tissue sarcoma (STS) of the extremities undergoing re-excision after previous unplanned surgery...
  13. ncbi request reprint Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution
    Elisabetta Pennacchioli
    Department of Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian, 1, 20133, Milan, Italy
    Ann Surg Oncol 14:553-9. 2007
    ..To explore the prognostic impact of isolated limb perfusion (ILP) in locally advanced extremity soft tissue sarcomas (ESTS)...
  14. pmc Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas
    Elena Tamborini
    Experimental Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Tumori Milano, Via G Venezian 1, 20133 Milano, Italy
    Neuro Oncol 12:776-89. 2010
    ....
  15. doi request reprint Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up
    P G Casali
    Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, Italy
    Ann Oncol 19:ii89-93. 2008
  16. ncbi request reprint Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution
    Matteo Anghileri
    Department of Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer 107:1065-74. 2006
    ..The authors explored the prognostic factors and clinical outcomes of patients who had malignant peripheral nerve sheath tumors (MPNST) with and without neurofibromatosis type 1 (NF-1)...
  17. doi request reprint Leiomyosarcoma and sarcoma with myogenic differentiation: two different entities or 2 faces of the same disease?
    Chiara Colombo
    Department of Surgery Sarcoma Service, Scientific Institutes for Recovery and Cure IRCCS Foundation, National Cancer Institute, Milan, Italy
    Cancer 118:5349-57. 2012
    ..The objective of this study was to evaluate whether the distinction between leiomyosarcomas (LMS) and sarcomas with myogenic differentiation (SMD), based on the expression of muscular markers, has any clinical implications...
  18. doi request reprint The prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of surgically treated patients at a single institution
    Chiara Mussi
    Department of Surgery, Foundation IRCCS for National Cancer Institute, Milan, Italy
    Cancer 113:1657-65. 2008
    ..A series of patients with well differentiated (WD)/dedifferentiated (DD) retroperitoneal liposarcoma (RLS) was studied to evaluate the prognostic value of the presence, extension, and grade of the DD component...
  19. ncbi request reprint Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution
    Dario Baratti
    Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
    Ann Surg Oncol 14:3542-51. 2007
    ..Typically, it occurs superficially as single/multiple nodules (nodular ES), or in deeper tissues as a mass. The correlation between initial presentation and clinical outcome was investigated...
  20. ncbi request reprint Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure
    Alessandro Gronchi
    Department of Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian, 1, 20133, Milano, Italy
    Ann Surg Oncol 14:1583-90. 2007
    ..We explored the prognostic meaning of local relapse and surgical margins in adult soft tissue sarcoma of the extremities...
  21. doi request reprint Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib
    Silvia Stacchiotti
    Adult Sarcoma Medical Oncology Unit, Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Int J Cancer 129:1761-72. 2011
    ..In conclusion, DFSP-derived FS maintains the fusion-gene, being sensitive to imatinib. However, responses are short-lasting. Secondary resistance to imatinib is not related to PDGFRB...
  22. ncbi request reprint Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system
    Luigi Mariani
    Unit of Medical Statistics and Biometry, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer 103:402-8. 2005
    ..A nomogram for predicting long term tumor-specific death in patients with soft tissue sarcoma (STS) was developed at the Memorial Sloan-Kettering Cancer Center (MSKCC)...
  23. doi request reprint Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: an imaging, biochemical and molecular modeling study
    Palma Dileo
    Department of Medical Oncology, SS Trattamento Medico dei Sarcomi dell Adulto, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
    Int J Cancer 128:983-90. 2011
    ....
  24. doi request reprint Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution
    Roberta Sanfilippo
    Department of Cancer Medicine, Istituto Nazionale Tumori, Milan, Italy
    Ann Surg Oncol 18:720-5. 2011
    ..quot; The aim of this retrospective case series analysis was to investigate prognostic factors and the clinical outcome of a cohort of patients with myxofibrosarcoma treated at a single institution...
  25. doi request reprint Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single institution
    Elisabetta Pennacchioli
    Department of Surgery, Istituto Nazionale Tumori, Milan, Italy
    Ann Surg Oncol 17:3229-33. 2010
    ..A comprehensive retrospective review was performed of clinical presentation, treatment, outcome, and patterns of failure in a consecutive series of patients with localized or metastatic ASPS between 1975 and 2008...
  26. doi request reprint Localised thoracic sarcomas: outcome improvement over time at a single institution
    Leonardo Duranti
    Division of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, Milan, Italy
    Eur J Cancer 49:2689-97. 2013
    ..To assess changes in survival over time in patients affected by thoracic soft tissue sarcomas treated at a single institution...
  27. ncbi request reprint Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
    Federica Grosso
    Cancer Medicine Department, Adult Sarcoma Medical Treatment Unit, IRCCS Foundation National Cancer Institute, Milan, Italy
    Lancet Oncol 8:595-602. 2007
    ....
  28. pmc Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors?
    Francesca Miselli
    Experimental Molecular Pathology Unit, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Transl Oncol 1:177-86. 2008
    ..Our descriptive results support the idea that GISTs activate autophagy rather than apoptosis in response to imatinib treatment and that their molecular makeup includes fingerprints of autophagy...
  29. doi request reprint Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma
    Tiziana Negri
    Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Genes Chromosomes Cancer 51:111-26. 2012
    ..2011 Wiley Periodicals, Inc...
  30. doi request reprint Surgical technique, morbidity, and outcome of primary retroperitoneal sarcoma involving inferior vena cava
    Marco Fiore
    Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Ann Surg Oncol 19:511-8. 2012
    ..The aim of the study was to review a monoinstitutional series of IVC resections for RSTS (mainly IVC leiomyosarcoma), focusing on the type of vascular replacement, morbidity, and oncologic outcome...
  31. doi request reprint Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment
    Marco Fiore
    Department of Surgery, Istituto Nazionale Tumori, Milan, Italy
    Ann Surg Oncol 16:2587-93. 2009
    ..The disease remained stable in more than half of patients. This study was designed to evaluate this approach on the natural history of the disease in a larger series of patients...
  32. doi request reprint Response to sunitinib malate in advanced alveolar soft part sarcoma
    Silvia Stacchiotti
    Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Clin Cancer Res 15:1096-104. 2009
    ..The tumor vascular pattern prompted us to use sunitinib malate (SM), a tyrosine kinase inhibitor with antiangiogenic properties...
  33. ncbi request reprint Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas
    Elena Tamborini
    Experimental Molecular Pathology, Department of Pathology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy
    Clin Cancer Res 12:6920-8. 2006
    ..This article describes the results of comprehensive molecular/biochemical analyses of the three receptors targeted by the drug (PDGFRB, PDGFRA, and KIT) in a series of 31 chordoma patients...
  34. ncbi request reprint Imatinib mesylate in chordoma
    Paolo G Casali
    Adult Sarcoma Medical Oncology Unit, Department of Cancer Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer 101:2086-97. 2004
    ..To the authors' knowledge, no effective medical therapy currently is available for advanced chordoma. Imatinib mesylate is a tyrosine kinase inhibitor targeting platelet-derived growth factor receptor-beta (PDGFRB), BCR-ABL, and KIT...
  35. pmc Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib
    Silvia Stacchiotti
    Department of Cancer Medicine, Adult Sarcoma Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori Milan, Via Venezian 1, 20133, Milan, Italy
    Clin Sarcoma Res 2:22. 2012
    ..abstract:..
  36. ncbi request reprint A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient
    Elena Tamborini
    Department of Pathology, Istituto Nazionale per lo Studio e al Cura dei Tumori, Milan, Italy
    Gastroenterology 127:294-9. 2004
    ..Molecular mechanisms have been reported in CML and GIST for primary resistance, whereas extensive studies on the mechanisms responsible for secondary resistance have been almost exclusively reported for CML...
  37. pmc Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib
    Silvia Stacchiotti
    Adult Mesenchymal Tumor Medical Oncology Unit, Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale Tumori Milan, Milan, Italy
    Clin Sarcoma Res 3:8. 2013
    ..We report on two PVNS patients who responded to imatinib after failure to nilotinib, another CSF1-receptor inhibitor...
  38. ncbi request reprint Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution
    Andrea Ferrari
    Pediatric Oncology Unit, Istituto Nazionale Tumori, Milan, Italy
    Cancer 98:571-80. 2003
    ..Published series have reported definitively worse results for adults with RMS compared with children with RMS. This finding casts doubt on whether RMS is the same disease in adults as it is in children...
  39. doi request reprint Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy
    Silvia Stacchiotti
    Department of Cancer Medicine, Scientific Institute for Research and Treatment Foundation, National Cancer Institute, Milan, Italy
    Cancer 118:5857-66. 2012
    ....
  40. doi request reprint Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?
    C Mussi
    Melanoma and Sarcoma Unit, Department of Surgery, Istituto Nazionale Tumori, Milan, Italy
    Ann Oncol 21:403-8. 2010
    ..Primary end points were progression-free survival (PFS) and disease-specific survival (DSS)...
  41. ncbi request reprint Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution
    Alessandro Gronchi
    Department of Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
    Cancer 100:2448-55. 2004
    ..Several series of patients with retroperitoneal sarcoma were reported, providing widely variable data regarding local and distant failure...
  42. doi request reprint Response to imatinib plus sirolimus in advanced chordoma
    S Stacchiotti
    Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Ann Oncol 20:1886-94. 2009
    ..Imatinib (IM) is active in advanced chordoma. The evidence of upstream and/or downstream mammalian target of rapamycin (mTOR) pathway activation prompted us to combine an mTOR inhibitor, sirolimus, to IM in IM-resistant advanced chordoma...
  43. ncbi request reprint Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution
    A Gronchi
    Department of Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian, 1 20133 Milano, Italy
    J Clin Oncol 23:96-104. 2005
    ..To explore the prognostic effect of microscopic marginal status after surgery for extremity soft tissue sarcomas...
  44. doi request reprint Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST)
    M Fiore
    Department of Surgery, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    Eur J Surg Oncol 35:739-45. 2009
    ..To explore the effect of preoperative imatinib mesylate (IM) in patients with unresectable or locally advanced primary gastrointestinal stromal tumor (GIST)...
  45. ncbi request reprint Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma
    F Grosso
    Cancer Medicine Dept, Adult Sarcoma Medical Oncology Unit, Istituto Nazionale Tumori, Via G Venezian 1, 20133 Milano, Italy
    Eur J Cancer 42:1484-90. 2006
    ..Among STS patients, 9% had objective responses. In this unselected patient series, premedication with dexamethasone strongly reduced drug-induced hepatotoxicity and myelosuppression...
  46. doi request reprint Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series
    F Grosso
    Adult Sarcoma Medical Treatment Unit, Cancer Medicine Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Ann Oncol 20:1439-44. 2009
    ..A previous analysis showed that myxoid liposarcomas (MLS) are particularly sensitive to the drug. We report on the long-term efficacy of trabectedin in a subgroup of that series...
  47. doi request reprint The burden of rare cancers in Europe
    Gemma Gatta
    Fondazione IRCCS Istituto Nazionale dei Tumori, Dipartimento di Medicina Predittiva e per la Prevenzione, Unità di Epidemiologia Valutativa, Via Venezian, 1, 20133, Milan, Italy
    Adv Exp Med Biol 686:285-303. 2010
    ..The burden indicators were estimated and are provided in this chapter...
  48. ncbi request reprint Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution
    A Gronchi
    Department of Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Clin Oncol 21:1390-7. 2003
    ..To explore prognostic factors in surgically treated aggressive fibromatosis (extra-abdominal desmoid tumor)...
  49. doi request reprint Role of macrophage targeting in the antitumor activity of trabectedin
    Giovanni Germano
    Department Immunology and Inflammation, IRCCS Clinical and Research Institute Humanitas, 20089 Rozzano, Milan, Italy
    Cancer Cell 23:249-62. 2013
    ..This unexpected property may be exploited in different therapeutic strategies...
  50. ncbi request reprint Postoperative radiotherapy for synovial sarcoma of the head and neck during pregnancy: clinical and technical management and fetal dose estimates
    Ester Orlandi
    Department of Radiation Oncology I, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 93:45-52. 2007
    ....
  51. doi request reprint Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up
    P G Casali
    Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, Italy
    Ann Oncol 19:ii35-8. 2008
  52. ncbi request reprint Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis
    A Azzarelli
    Musculo-Skeletal Surgical Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer 92:1259-64. 2001
    ..CONCLUSIONS: Methotrexate plus vinblastine given every 7-10 days for several months is associated with prolonged stable disease in a substantial subset of patients with advanced (inoperable) aggressive fibromatosis...
  53. doi request reprint Rare cancers are not so rare: the rare cancer burden in Europe
    Gemma Gatta
    Department of Preventive and Predictive Medicine, Fondazione IRCSS, Istituto Nazionale dei Tumori, Via Venezian 1, Milan, Italy
    Eur J Cancer 47:2493-511. 2011
    ..The project Surveillance of Rare Cancers in Europe (RARECARE) provides estimates of the incidence, prevalence and survival of rare cancers in Europe based on a new and comprehensive list of these diseases...
  54. ncbi request reprint Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients
    E Tamborini
    Experimental Molecular Pathology, Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Oncogene 25:6140-6. 2006
    ..The application of molecular simulations allowed us to quantify the interactions between the mutated receptors and imatinib, and to propose a molecular rationale for this type of drug resistance...
  55. doi request reprint Adjuvant therapy for high-risk soft tissue sarcoma in the adult
    Alessandro Gronchi
    Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Curr Treat Options Oncol 14:415-24. 2013
    ..It is probable that in the future the biological background of the different soft tissue sarcoma subtypes will guide the selection of therapies as well as the setting to deliver them...
  56. doi request reprint Myxoid liposarcoma and the mammalian target of rapamycin pathway
    Roberta Sanfilippo
    Adult Mesenchymal Tumor Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Curr Opin Oncol 25:379-83. 2013
    ..MRCLs should be included among these, as various molecular aberrations of the mTOR pathway have been recently reported...
  57. ncbi request reprint Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
    Jaap Verweij
    Department of Medical Oncology, Erasmus University Medical Centre, Groene Hilledijk 301, 3075 EA Rotterdam, Netherlands
    Lancet 364:1127-34. 2004
    ..Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GIST). We aimed to assess dose dependency of response and progression-free survival with imatinib for metastatic GIST...
  58. ncbi request reprint Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas?
    Tommaso De Pas
    Oncology 64:186-8. 2003
  59. ncbi request reprint Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
    John R Zalcberg
    Department of Medical Oncology, Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett Street, Melbourne, VIC 8006, Australia
    Eur J Cancer 41:1751-7. 2005
    ..1% of patients were still alive and progression free one year after cross-over. We conclude that a cross-over to high-dose imatinib is feasible and safe in GIST patients who progress on low-dose therapy...
  60. ncbi request reprint Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Grou
    Martine van Glabbeke
    European Organisation for Research and Treatment of Cancer Data Center, Av E Mounier, 83, Bte 8, B1200 Brussels, Belgium
    J Clin Oncol 23:5795-804. 2005
    ..This study is based on the European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group randomized trial comparing two doses of imatinib in advanced disease...
  61. ncbi request reprint Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate
    Marco Fiore
    Department of Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milano, Italy
    J Clin Oncol 23:7669-75. 2005
    ..The aim of this retrospective analysis was to explore the outcome of patients with primary or recurrent DFSP...
  62. ncbi request reprint KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
    Maria Debiec-Rychter
    Department of Human Genetics, University of Leuven and University Hospital Gasthuisberg, O and N Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Eur J Cancer 42:1093-103. 2006
    ..Our findings suggest the need for differential treatment of patients with GISTs, with KIT exon 9 mutant patients benefiting the most from the 800 mg daily dose of the drug...
  63. ncbi request reprint Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Gr
    Martine van Glabbeke
    EORTC Data Center, Av E Mounier, 83, Bte 8, B1200, Brussels, Belgium
    Eur J Cancer 42:2277-85. 2006
    ..A multivariate risk calculator that can be used in the clinic for individual patients is proposed...
  64. ncbi request reprint Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
    George D Demetri
    Ludwig Center at Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Lancet 368:1329-38. 2006
    ....
  65. ncbi request reprint Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005
    Jaap Verweij
    Erasmus University Medical Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 43:974-8. 2007
    ..In 2 patients (0.2%) a possible cardiotoxic effect of imatinib could not fully be excluded. The current analysis of a large randomised prospective study could not confirm previous suggestions of imatinib induced cardiac toxicity...
  66. ncbi request reprint Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma
    Elena Tamborini
    Experimental Molecular Pathology, Department of Pathology and Departments of Experimental Oncology, Istituto Nazionale per lo Studio e al Cura dei Tumori, Via G Venezian, 1, 20133 Milan, Italy
    Clin Cancer Res 10:938-43. 2004
    ....
  67. ncbi request reprint A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake
    Deborah Mannavola
    Department of Medical Sciences, University of Milan and Endocrine Unit, Fondazione Policlinico Istituto di Ricovero e Cura a Carattere Scientifico, 20122 Milan, Italy
    J Clin Endocrinol Metab 92:3531-4. 2007
    ..New York, NY) is a multitarget inhibitor of tyrosine kinases for the treatment of some human cancers. A myxedematous coma in a patient treated with sunitinib for a gastrointestinal stromal tumor was unexpectedly observed...